Profile data is unavailable for this security.
About the company
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
- Revenue in HUF (TTM)811.42bn
- Net income in HUF229.13bn
- Incorporated1923
- Employees11.60k
- LocationRichter Gedeon Vegyeszeti Gyar NyrtGyomroi ut 19-21.BUDAPEST 1103HungaryHUN
- Phone+36 14314000
- Fax+36 12606650
- Websitehttps://www.gedeonrichter.com/hu-hu/
More ▼
Mergers & acquisitions
| Acquired company | RICHTER:BUD since announced | Transaction value |
|---|---|---|
| BCI Pharma SAS | 15.07% | 12.89m |
| Estetra SA | 15.69% | 187.69m |
| Mithra Pharmaceuticals SA-Undisclosed France Assets | 15.69% | -- |
| Richter-Helm Biologics GmbH & Co KG | 11.77% | 44.07m |
| Richter-Helm Biotec GmbH & Co. KG | 11.77% | 77.94m |
Data delayed at least 15 minutes, as of Nov 22 2024 11:48 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | 132.90bn | -122.10bn | 1.85tn | 545.00 | -- | 51.20 | -- | 13.93 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| IPCA Laboratories Ltd | 396.53bn | 30.72bn | 1.86tn | 17.34k | 60.37 | 5.96 | 37.42 | 4.68 | 26.07 | 26.07 | 336.37 | 264.10 | 0.7483 | 1.12 | 4.78 | 4,922,642.00 | 5.88 | 10.33 | 9.00 | 13.52 | 67.36 | 59.16 | 7.85 | 12.25 | 1.32 | 25.33 | 0.129 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| GlaxoSmithKline Pharmaceuticals Limited | 165.45bn | 31.37bn | 1.87tn | 3.21k | 59.84 | 24.00 | 53.99 | 11.27 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Krka d.d. Novo Mesto | 781.65bn | 147.99bn | 1.87tn | 11.75k | 11.87 | 1.95 | 9.98 | 2.39 | 11.67 | 11.67 | 61.64 | 71.04 | 0.6951 | 1.35 | 3.87 | 162,896.80 | 13.14 | 12.64 | 15.77 | 15.12 | 56.55 | 57.29 | 18.90 | 18.71 | 2.47 | -- | 0.0057 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Glenmark Pharmaceuticals Ltd | 569.12bn | -47.32bn | 1.92tn | 14.99k | -- | 4.90 | -- | 3.38 | -36.13 | -31.05 | 434.11 | 299.29 | 0.6951 | 1.53 | 4.04 | 8,171,082.00 | -5.64 | 1.02 | -8.51 | 1.43 | 65.64 | 59.47 | -8.11 | 1.43 | 1.00 | 2.56 | 0.1741 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| ADMA Biologics Inc | 150.31bn | 26.75bn | 1.98tn | 624.00 | 77.08 | 21.71 | 65.95 | 13.15 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 3.97bn | -110.13bn | 1.99tn | 253.00 | -- | 3.37 | -- | 501.91 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 811.42bn | 229.13bn | 2.01tn | 11.60k | 8.66 | 1.68 | 7.25 | 2.48 | 1,248.46 | 1,248.46 | 4,419.54 | 6,425.20 | 0.5959 | 1.36 | 3.77 | 69,931,480.00 | 16.92 | 11.64 | 19.01 | 13.28 | 68.64 | 58.18 | 28.40 | 18.93 | 2.03 | -- | 0.0454 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
| Hikma Pharmaceuticals Plc | 1.18tn | 111.93bn | 2.06tn | 8.97k | 18.57 | 2.29 | 10.92 | 1.74 | 1.01 | 1.01 | 10.74 | 8.22 | 0.6374 | 1.77 | 3.38 | 267,324.30 | 6.13 | 8.19 | 8.47 | 11.30 | 47.40 | 50.29 | 9.61 | 13.77 | 0.9775 | 7.81 | 0.3568 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Humanwell Healthcare Group Co Ltd | 1.39tn | 106.09bn | 2.11tn | 17.68k | 19.64 | 2.17 | -- | 1.52 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Siegfried Holding AG | 568.74bn | 56.78bn | 2.21tn | 3.80k | 36.96 | 5.22 | 23.24 | 3.88 | 29.87 | 29.87 | 299.09 | 211.39 | 0.7046 | 2.00 | 3.80 | 326,556.30 | 7.06 | 6.51 | 8.64 | 7.98 | 25.87 | 23.24 | 10.03 | 9.06 | 1.40 | 14.34 | 0.3217 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Ono Pharmaceutical Co Ltd | 1.23tn | 241.70bn | 2.21tn | 3.85k | 8.68 | 1.05 | 7.69 | 1.80 | 201.26 | 201.26 | 1,026.05 | 1,665.85 | 0.4987 | 2.37 | 3.47 | 125,694,000.00 | 9.80 | 11.95 | 11.16 | 13.73 | 75.38 | 74.11 | 19.65 | 23.89 | 2.80 | -- | 0.1702 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
Data as of Nov 22 2024. Currency figures normalised to Richter Gedeon Vegyeszeti Gyar Nyrt's reporting currency: Hungarian Forint HUF
22.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 8.82m | 4.73% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 5.43m | 2.92% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 30 Sep 2024 | 4.90m | 2.63% |
| Orbis Investment Management Ltd.as of 31 Dec 2023 | 4.44m | 2.39% |
| Hermes Investment Management Ltd.as of 30 Sep 2024 | 3.96m | 2.13% |
| Seafarer Capital Partners LLCas of 30 Sep 2024 | 3.55m | 1.91% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 3.34m | 1.79% |
| Templeton Asset Management Ltd.as of 30 Sep 2024 | 2.78m | 1.49% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 2.66m | 1.43% |
| Schroder Investment Management Ltd.as of 30 Sep 2024 | 2.57m | 1.38% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
